Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts. more
Time Frame | ACRV | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.96% | -2.12% | -3% |
1-Month Return | 3.23% | -3.42% | -0.73% |
3-Month Return | -10.17% | -11.13% | 2.87% |
6-Month Return | 2.91% | -5.74% | 7.17% |
1-Year Return | 40.97% | 3.97% | 25.31% |
3-Year Return | -59.68% | 1.05% | 28.38% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | 13.00K | 832.00K | 1.09M | 536.00K | [{"date":"2020-12-31","value":1.19,"profit":true},{"date":"2021-12-31","value":75.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":48.95,"profit":true}] | |
Gross Profit | (13.00K) | (832.00K) | (1.09M) | (536.00K) | [{"date":"2020-12-31","value":-1300000,"profit":false},{"date":"2021-12-31","value":-83200000,"profit":false},{"date":"2022-12-31","value":-109500000,"profit":false},{"date":"2023-12-31","value":-53600000,"profit":false}] | |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] | |
Operating Expenses | 3.17M | 16.18M | 32.66M | 66.70M | [{"date":"2020-12-31","value":4.75,"profit":true},{"date":"2021-12-31","value":24.26,"profit":true},{"date":"2022-12-31","value":48.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (3.17M) | (16.18M) | (32.66M) | (67.24M) | [{"date":"2020-12-31","value":-316800000,"profit":false},{"date":"2021-12-31","value":-1618400000,"profit":false},{"date":"2022-12-31","value":-3265700000,"profit":false},{"date":"2023-12-31","value":-6723700000,"profit":false}] | |
Total Non-Operating Income/Expense | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Pre-Tax Income | (5.31M) | (16.24M) | (31.17M) | (60.39M) | [{"date":"2020-12-31","value":-530600000,"profit":false},{"date":"2021-12-31","value":-1624300000,"profit":false},{"date":"2022-12-31","value":-3116700000,"profit":false},{"date":"2023-12-31","value":-6038800000,"profit":false}] | |
Income Taxes | (193.30K) | (199.56K) | (1.49M) | 1.00 | [{"date":"2020-12-31","value":-19329700,"profit":false},{"date":"2021-12-31","value":-19955800,"profit":false},{"date":"2022-12-31","value":-149000000,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | |
Income After Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income From Continuous Operations | (5.31M) | (16.24M) | (31.17M) | (50.06M) | [{"date":"2020-12-31","value":-530600000,"profit":false},{"date":"2021-12-31","value":-1624300000,"profit":false},{"date":"2022-12-31","value":-3116700000,"profit":false},{"date":"2023-12-31","value":-5006500000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (5.31M) | (16.24M) | (29.68M) | (60.39M) | [{"date":"2020-12-31","value":-530600000,"profit":false},{"date":"2021-12-31","value":-1624300000,"profit":false},{"date":"2022-12-31","value":-2967700000,"profit":false},{"date":"2023-12-31","value":-6038800000,"profit":false}] | |
EPS (Diluted) | - | - | (1.31) | (2.73) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-131,"profit":false},{"date":"2023-12-31","value":-273,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
ACRV | |
---|---|
Cash Ratio | 12.65 |
Current Ratio | 12.75 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ACRV | |
---|---|
ROA (LTM) | -24.41% |
ROE (LTM) | -37.78% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ACRV | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.08 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.92 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ACRV | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.08 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Acrivon Therapeutics, Inc. Common Stock (ACRV) share price today is $6.71
Yes, Indians can buy shares of Acrivon Therapeutics, Inc. Common Stock (ACRV) on Vested. To buy Acrivon Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACRV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Acrivon Therapeutics, Inc. Common Stock (ACRV) via the Vested app. You can start investing in Acrivon Therapeutics, Inc. Common Stock (ACRV) with a minimum investment of $1.
You can invest in shares of Acrivon Therapeutics, Inc. Common Stock (ACRV) via Vested in three simple steps:
The 52-week high price of Acrivon Therapeutics, Inc. Common Stock (ACRV) is $11.9. The 52-week low price of Acrivon Therapeutics, Inc. Common Stock (ACRV) is $3.19.
The price-to-earnings (P/E) ratio of Acrivon Therapeutics, Inc. Common Stock (ACRV) is
The price-to-book (P/B) ratio of Acrivon Therapeutics, Inc. Common Stock (ACRV) is 1.08
The dividend yield of Acrivon Therapeutics, Inc. Common Stock (ACRV) is 0.00%
The market capitalization of Acrivon Therapeutics, Inc. Common Stock (ACRV) is $208.30M
The stock symbol (or ticker) of Acrivon Therapeutics, Inc. Common Stock is ACRV